OncoMatch/Clinical Trials/NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Is NCT06484920 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ATRA and Pembrolizumab for relapsed hodgkin lymphoma.
Treatment: ATRA · Pembrolizumab — This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — relapsed HL: at least 1 prior line; PMBCL: refractory to first-line; other B-cell NHLs: at least 2 prior lines
HL after failure of at least 1 prior line of systemic therapy; PMBCL that is refractory to first-line therapy; Other B-cell NHLs after failure of at least 2 prior lines of systemic therapy
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-cancer monoclonal antibody
Exception: within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Cannot have received: chemotherapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Cannot have received: targeted small molecule therapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Cannot have received: radiation therapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,500 /mcL; Platelets ≥100,000 / mcL; Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment); INR and aPTT ≤1.5 x ULN (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
Kidney function
calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) calculated creatinine clearance ≥ 60 mL/min
Liver function
Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN (patients with known Gilbert disease who have bilirubin levels ≤ 3 x ULN may be enrolled). AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR 5 X ULN for subjects with liver metastases. Albumin >2.5 mg/dL.
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 10 days prior to the first study treatment: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital · Indianapolis, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify